Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year. Net income attributable to Gilead was $1 billion, or $0.80 per share, compared to $19 million, or $0.02 per share, last year. Adjusted EPS amounted to $1.37. For the full year of 2023, […]
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year. Net income attributable to Gilead was $1 billion, or $0.80 per share, compared to $19 million, or $0.02 per share, last year. Adjusted EPS amounted to $1.37. For the full year of 2023, […]
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year.
Net income attributable to Gilead was $1 billion, or $0.80 per share, compared to $19 million, or $0.02 per share, last year. Adjusted EPS amounted to $1.37.
For the full year of 2023, the company expects adjusted EPS of $6.60-7.00.
